<DOC>
	<DOCNO>NCT01055600</DOCNO>
	<brief_summary>This Phase IV study evaluate eltrombopag concentration breast milk nursing mother take market eltrombopag ( PROMACTAÂ® ) . Up 10 subject ( mother-infant pair ) many 10 study center US enrol . Nursing mother register PROMACTA Pregnancy Registry offer option participate trial continue take commercial eltrombopag post-delivery decide breastfeed infant . Information collect diary . Breast milk sample collect infant feeding 24 hour period eltrombopag dose evaluate eltrombopag concentration breast milk . Mothers also give option pharmacokinetic ( PK ) blood sample collect infant .</brief_summary>
	<brief_title>Milk-only Lactation Study Patients Eltrombopag</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Mother registered PROMACTA Pregnancy Registry meet enrollment criterion define PROMACTA Pregnancy Registry study ( 113327 ) . Mother continue take eltrombopag . Mother receive 7 consecutive eltrombopag dose prior milk sample collection . Infant 4 week 26 week age time milk sample . Exclusively breastfeed motherinfant pair ; either via breast express milk mother . Mother capable give write informed consent , include compliance requirement restriction list consent form . Infant born complication could impact ability participate study . Breastfeeding well establish motherinfant pair ( e.g. , poor latch infant low milk supply ) . Infants supplement formula consume solid food . Unwillingness inability mother follow procedure outline protocol . Mother mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>26 Weeks</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>eltrombopag</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PROMACTA</keyword>
	<keyword>lactation</keyword>
	<keyword>milk-only study</keyword>
</DOC>